Dr. Debu Tripathy Discusses The Goal of the SystHERs Registry

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20Подробнее

Dr. Debu Tripathy Describes Intratumoral HeterogeneityПодробнее

Debu Tripathy, MD discusses what will be most impactful at the 2021 Miami Breast Cancer Conference®Подробнее

Dr. Debu Tripathy Reviews the Phase III CONFIRM TrialПодробнее

Dr. Debu Tripathy on the CDK4/6 Inhibitor PD 0332991 in ER-Positive Advanced Breast CancerПодробнее

Dr. Debu Tripathy Previews the Phase II GRN1005 StudyПодробнее

Dr. Debu Tripathy on Further Investigation Into Immunotherapies in Breast CancerПодробнее

Dr. Tripathy Provides an Overview of the SystHERs RegistryПодробнее

Dr. Debu Tripathy Gives an Overview of Targeted Therapies for Breast CancerПодробнее

Personalized Medicine in the Genomic Age of Breast Cancer by Dr. TripathyПодробнее

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patientsПодробнее

Dr. Tripathy Discusses Breast Cancer Gene ProfilingПодробнее

Dr. Tripathy Discusses Lurbinectedin in Breast CancerПодробнее

Debu Tripathy, MD discusses what is new at the 39th Annual Miami Breast Cancer Conference®Подробнее

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast CancerПодробнее

Dr. Tripathy on Personalized Therapies in Advanced Breast CancerПодробнее

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trialПодробнее

Debu Tripathy, MD discusses the impact of covid on breast cancerПодробнее

Dr. Tripathy Describes the Benefits of the PER ConferencesПодробнее